# Lauren Silverman

> Lauren Silverman is a Series B investor at Novartis Venture Fund backing Biotechnology. See 7 investments, check sizes, portfolio and contact details…

- Type: Angel Investor
- Fund: [Novartis Venture Fund](https://shizune.co/investors/profile/novartis-venture-fund)
- Location: Boston, United States
- Total investments: 7
- Last investment: Sep 2015
- Lead investor: 14%
- Last updated: Oct 2026
- LinkedIn: http://www.linkedin.com/pub/lauren-silverman/3/9b4/718

Lauren Silverman is a Series B investor at Novartis Venture Fund in Boston focused on Biotechnology and Therapeutics. Lauren Silverman is based out of Cambridge, Massachusetts and is the Managing Director of Novartis Venture Fund. Lauren previously worked at Pfizer as a Director of Business Development & Licensing. Lauren Silverman attended the University of Utah.

## Contacts

5 contacts available for Lauren Silverman: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/dr-lauren-silverman?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 57% |
| Therapeutics | 3 | 43% |
| Pharmaceutical | 2 | 29% |
| Medical | 1 | 14% |
| Hospital | 1 | 14% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 43% |
| Series A | 1 | 14% |
| Series D | 1 | 14% |
| Funding Round | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Proteostasis Therapeutics | Proteostasis Therapeutics is discovering and developing novel small molecule therapeutics designed to control the body's protein homeostasis, or Proteostasis Network. The Proteostasis Network maintains the body's natural balance of proteins to protect us from numerous diseases. These novel therapies, or Proteostasis Regulators, aredesigned to treat multiple genetic and degenerative disorders associated with deficiencies of the Proteostasis Network, such as emphysema, type II diabetes, Alzheimer's Disease and Huntington's Disease. | $37M | Series B | Sep 08, 2015 | http://www.proteostasis.com/ |
| Viamet Pharmaceuticals | Viamet Pharmaceuticals discovers and develops "best-in-class" inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, their Metallophileâ„¢ Technology. Viamet's disruptive Metallophileâ„¢ technology is based on their world-class expertise in bioinorganic chemistry and metalloenzymes and allowsthem to identify validated targets with high therapeutic and commercial potential; leverage existing metalloenzyme inhibitors as the basis for Viamet's best-in-class analogs; and rapidly and cost-effectively generate best-in-class, patentable, small molecule compounds by optimizing the metal-binding component of existing inhibitors. | $60M | Series D | Oct 21, 2014 | http://www.viamet.com |
| Celladon | Celladon Corporation, a biotechnology company, develops and manufactures molecular therapies for the treatment of heart failure. Its products include SERCA2a, an enzyme that regulates calcium cycling and contractility in heart muscle cells; and MYDICAR, an enzyme replacement therapy for heart failure. Celladon was founded in 2000 and is based in LaJolla, California. | $43M |  | Feb 15, 2012 | http://www.celladon.net |
| Pulmatrix | Pulmatrix is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is initially focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaledanti-fungal for patients with ABPA, and PUR1800, a narrow spectrum kinase inhibitor in lung cancer. Pulmatrix's product candidates are based on iSPERSE™, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by achieving optimal local drug concentrations and reducing systemic side effects to improve patient outcomes. | $14M | Series B | Aug 15, 2011 | http://www.pulmatrix.com |
| Pulmatrix | Pulmatrix is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is initially focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaledanti-fungal for patients with ABPA, and PUR1800, a narrow spectrum kinase inhibitor in lung cancer. Pulmatrix's product candidates are based on iSPERSE™, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by achieving optimal local drug concentrations and reducing systemic side effects to improve patient outcomes. | $30.2M | Series B | Nov 02, 2009 | http://www.pulmatrix.com |
| Viamet Pharmaceuticals | Viamet Pharmaceuticals discovers and develops "best-in-class" inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, their Metallophileâ„¢ Technology. Viamet's disruptive Metallophileâ„¢ technology is based on their world-class expertise in bioinorganic chemistry and metalloenzymes and allowsthem to identify validated targets with high therapeutic and commercial potential; leverage existing metalloenzyme inhibitors as the basis for Viamet's best-in-class analogs; and rapidly and cost-effectively generate best-in-class, patentable, small molecule compounds by optimizing the metal-binding component of existing inhibitors. | $25M | Series B | Jul 07, 2009 | http://www.viamet.com |
| Proteostasis Therapeutics | Proteostasis Therapeutics is discovering and developing novel small molecule therapeutics designed to control the body's protein homeostasis, or Proteostasis Network. The Proteostasis Network maintains the body's natural balance of proteins to protect us from numerous diseases. These novel therapies, or Proteostasis Regulators, aredesigned to treat multiple genetic and degenerative disorders associated with deficiencies of the Proteostasis Network, such as emphysema, type II diabetes, Alzheimer's Disease and Huntington's Disease. | $45M | Series A | Aug 25, 2008 | http://www.proteostasis.com/ |

7 of 7 investments shown.

## Co-investors
- [Hatteras Venture Partners](https://shizune.co/investors/profile/hatteras-venture-partners) — VC Fund, 3 deals together
- [5AM Ventures](https://shizune.co/investors/profile/5am-ventures) — VC Fund, 2 deals together
- [Astellas Venture Management](https://shizune.co/investors/profile/astellas-venture-management) — VC Fund, 2 deals together
- [F-Prime](https://shizune.co/investors/profile/f-prime-capital-partners) — VC Fund, 2 deals together
- [HealthCare Ventures](https://shizune.co/investors/profile/healthcare-ventures) — VC Fund, 2 deals together
- [Intersouth Partners](https://shizune.co/investors/profile/intersouth-partners) — VC Fund, 2 deals together

## About Novartis Venture Fund

VC Fund · Basel, Switzerland

Novartis Venture Fund's primary focus is on the development of novel therapeutics and platforms. They balance the therapeutic focus with investments in medical devices, diagnostics, or drug delivery systems. In their investments, they look for unmet needs and clinical impact, novel proprietary science, an understanding of mechanism, managementand board experience, and capital efficiency in the program.Novartis Venture Fund prefers to have their initial investment at the early stage to build the company and follow with additional investment in pace with the company's progress. Their approach involves larger focused investments, with anticipation of total investments up to USD 30 to 50 million per company over its life, but it can be as little as 100,000 USD to get started. They plan to increase their activities to lead or co-lead deals further and remain open to participating in larger syndicates.

5 contacts available at Novartis Venture Fund.

| Name | Title | Profile |
| --- | --- | --- |
| Aaron Nelson | Principal & Managing Director | https://shizune.co/investors/profile/aaron-nelson |
| Lauren Silverman | Managing Director | https://shizune.co/investors/profile/dr-lauren-silverman |
| Anja König | Global Head Novartis Venture Fund | https://shizune.co/investors/profile/dr-anja-knig |
| Bart Dzikowski | Managing Director, Head of Transactions & Legal | https://shizune.co/investors/profile/bart-dzikowski |
| Florent Gros | Managing Director | https://shizune.co/investors/profile/florent-gros |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Lauren Silverman invest in?

Lauren Silverman invests primarily in Biotechnology, Therapeutics and Pharmaceutical startups, most often at Series B and Series A stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Lauren Silverman?

Public channels for Lauren Silverman include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Lauren Silverman last invest?

The most recent investment recorded for Lauren Silverman closed in Sep 2015. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co